Products Categories
| CAS No.: | 51333-22-3 |
|---|---|
| Name: | Budesonide |
| Molecular Structure: | |
 |
|
| Formula: | C25H34O6 |
| Molecular Weight: | 430.59 |
| Synonyms: | Budeson;Respules;16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione;Entocort;Pregna-1,4-diene-3,20-dione,16,17- [butylidenebis(oxy)]-11,21-dihydroxy-,(11a,- 16R)-;Rhinocort;Budesonide (11beta,16alpha);Micronyl;Preferid;(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde;(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione;Cortivent;Prestwick_840;Rhinocort alpha; |
| EINECS: | 257-139-7 |
| Density: | 1.27 g/cm3 |
| Melting Point: | 221-232 °C (dec.) |
| Boiling Point: | 599.7 °C at 760 mmHg |
| Flash Point: | 201.8 °C |
| Solubility: | 21.53mg/L(temperature not stated) |
| Appearance: | white solid |
| Hazard Symbols: |
 Xn
|
| Risk Codes: | 20/21/22-36/37/38-40 |
| Safety: | 22-26-36 |
| PSA: | 93.06000 |
| LogP: | 2.71680 |
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 135062-02-1Repaglinide
- 161599-46-8Cytidine,5'-deoxy-5-fluoro-, 2',3'-diacetate
- 72956-09-3Carvedilol
- 8000-48-4Eucalyptus oil
- 15663-27-1Cisplatin
- 71963-77-4Artemether
- 14484-47-0Deflazacort
- 153-94-6D(+)-Tryptophan
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
1. Introduction of Budesonide
Budesonide is one kind of white crystalline powder or white solid. It is toxic. So the storage environment should be ventilate, low-temperature and dry. The Systematic (IUPAC) name of it is 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-3,20-dione. It belongs to Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Steroid and Hormone.
The Classification Code of it is Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-inflammatory; Autonomic Agents; Bronchodilator agents; Drug / Therapeutic Agent; Glucocorticoids; Hormone; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Human Data; Peripheral Nervous System Agents; Reproductive Effect; Respiratory System Agents.
2. Properties of Budesonide
Physical properties about Budesonide are:
(1)Melting Point: 221-232°C (dec.); (2)Index of Refraction: 1.592; (3)Molar Refractivity: 113.86 cm3; (4)Molar Volume: 336.4 cm3; (5)Surface Tension: 55.2 dyne/cm; (6)Density: 1.27 g/cm3; (7)Flash Point: 201.8 °C; (8)Enthalpy of Vaporization: 102.44 kJ/mol; (9)Boiling Point: 599.7 °C at 760 mmHg; (10)Vapour Pressure: 6.94E-17 mmHg at 25 °C; (11)XLogP3-AA: 2.5; (12)H-Bond Donor: 2; (13)H-Bond Acceptor: 6; (14)Rotatable Bond Count: 4; (15)Tautomer Count: 9; (16)Exact Mass: 430.235539; (17)MonoIsotopic Mass: 430.235539; (18)Topological Polar Surface Area: 93.1; (19)Heavy Atom Count: 31.
3. Structure Descriptors of Budesonide
(1)Canonical SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C
(2)InChIKey: VOVIALXJUBGFJZ-KWVAZRHASA-N
(3)Smiles: C1(C=C[C@@]2([C@H]3[C@H](C[C@@]4([C@@]5([C@H](C[C@@H]4[C@@H]3CCC2=C1)O[C@@H](CCC)O5)C(CO)=O)C)O)C)=O
(4)InChI: InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20-,21?,22+,23-,24-,25+/m0/s1
4. Toxicity of Budesonide
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | subcutaneous | 173mg/kg (173mg/kg) | GASTROINTESTINAL: ULCERATION OR BLEEDING FROM STOMACH BLOOD: CHANGES IN SPLEEN GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. |
| man | TCLo | inhalation | 34ug/kg (.034mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" | Australian and New Zealand Journal of Medicine. Vol. 22, Pg. 511, 1992. |
| mouse | LD50 | intraperitoneal | 179mg/kg (179mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. |
| mouse | LD50 | intravenous | 124mg/kg (124mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. |
| mouse | LD50 | oral | 4750mg/kg (4750mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. |
| mouse | LD50 | subcutaneous | 53600ug/kg (53.6mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. |
| rat | LD50 | intraperitoneal | 138mg/kg (138mg/kg) | BLOOD: CHANGES IN SPLEEN BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. |
| rat | LD50 | intravenous | 98900ug/kg (98.9mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. |
| rat | LD50 | oral | > 3200mg/kg (3200mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985. | |
| rat | LD50 | subcutaneous | 58400ug/kg (58.4mg/kg) | BLOOD: CHANGES IN SPLEEN BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 19 |
5. Physical Properties of Budesonide
| Physical Property | Value | Units | Temp (deg C) | Source |
|---|---|---|---|---|
| Melting Point | 226 dec | deg C | EXP | |
| log P (octanol-water) | 2.180 | (none) | EST | |
| Atmospheric OH Rate Constant | 1.28E-10 | cm3/molecule-sec | 25 | EST |
6. Safety information of Budesonide
Hazard Codes:
Xn Risk Statements: 40-36/37/38-20/21/22
R40: Limited evidence of a carcinogenic effect.
R36/37/38: Irritating to eyes, respiratory system and skin.
R20/21/22: Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 22-36-26
S22: Do not breathe dust.
S36: Wear suitable protective clothing.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
WGK Germany: 3
RTECS: TU3723000
Poison by subcutaneous, intravenous, and intraperitoneal routes. Moderately toxic by ingestion. An experimental teratogen. Other experimental reproductive effects. When heated to decomposition it emits acrid smoke and fumes.
7. Uses of Budesonide
Budesonide (CAS NO.51333-22-3) is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. It is also used for Crohn's disease (inflammatory bowel disease). It is used as an antiinflammatory agent. Budesonide is a non-halogenated glucocorticoid related to triamcinolone hexacetonide.As a pharmaceutical raw material, it can be used in the medicine.
-
Premium Related Products
